Putting It All Together What goes into a patient reported outcome? By Ed Silverman ARTICLE EXTRAS Your Drug Target Audience Designing a patient-reported outcome requires months of painstaking research and interaction with patients, says Alexandra Quittner, a professor of psychology and pediatrics at the University of Miami, who eight years ago began designing a questionnaire for Genentech and the Cystic Fibrosis Foundation that eventually spanned 18 study cite

Your Drug Target Audience Whether drug companies like it or not, the FDA is pushing patient-reported outcomes in trials. So what are they good for? By Ed Silverman ARTICLE EXTRAS Putting It All Together Bruce Montgomery remembers the moment he came faceto-face with a quality-of-life issue. It was the summer of 2004, and he had traveled to Maryland to meet with staffers at the Food and Drug Administration to discuss an inhaled antibiotic, which his company

THE TROUBLE WITH TECH TRANSFER Criticism from academics and industry, and fewer deals being made: What's going on? By Ed Silverman © GETTY IMAGES / JUMPSTART STUDIOS ARTICLE EXTRAS Fighting Tech Transfer and Winning Barry Merriman says he wants nothing to do with his university's technology transfer office. About three years ago, the researcher in the human

Fighting tech transfer - and winning By Ed Silverman ARTICLE EXTRAS The Trouble with Tech Transfer COURTESY OF LANCE CLAYTON I fought the Law: Chris Johnson Chris Johnson fought his tech transfer office and lived to tell the story. The computer science professor at the University o

By Ed Silverman Small World Globalization means broader definition of diversity, and broader opportunities. Weiyi Zheng says he loves his career in the New Jersey suburbs, but he wouldn't turn down an opportunity to return to his native China. And thanks to the increasing globalization of the pharma industry workforce, his employer just might give him the ch

In March, Ligand Pharmaceuticals, a San Diego-based biotech company, suffered a series of setbacks that prompted company executives to scramble to control the fallout and preserve its reputation.

Kenneth Giacin couldn't be more excited about California's Proposition 71.

Alan Nixon's misguided essay supporting the use of scientific data taken from experiments conducted on tortured humans by the Nazis demands a vigorous rebuttal. To my mind, Mr. Nixon's argument is spurious, offensive, and further underscores the need to emphasize the study of ethics in professional life, including the sciences. Using the Nazi data would be abhorrent. Mr. Nixon's mistaken impression that Nazi scientists were forced into their research conveniently overlooks the cruelty and un